---
title: "ImmuCell | 8-K: FY2026 Q2 Revenue: USD 7.2 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292237928.md"
datetime: "2026-07-09T20:10:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292237928.md)
  - [en](https://longbridge.com/en/news/292237928.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292237928.md)
generator: "portal-rs"
---

# ImmuCell | 8-K: FY2026 Q2 Revenue: USD 7.2 M

Revenue: As of FY2026 Q2, the actual value is USD 7.2 M.

#### Second Quarter 2026 Sales Highlights

ImmuCell Corporation reported total product sales of $7.2 million for the three months ended June 30, 2026, representing an 11.5% increase compared to the same period in 2025. Domestic sales grew by 27.7% to $6.2 million, while international sales decreased by -38.9% to $1.0 million for the quarter. Sales of Tri-Shield First Defense® increased by 8.3% to $4.9 million, and Dual-Force® and Other Sales rose by 19.1% to $2.3 million for the quarter.

#### First Six Months of 2026 Sales Highlights

For the six months ended June 30, 2026, total product sales reached $17.5 million, marking a 20.9% increase over the first six months of 2025. Domestic sales for this period were $16.0 million, an increase of 32.5%, while international sales were $1.6 million, a decrease of -35.7%. Tri-Shield First Defense® sales for the six months totaled $12.8 million, an increase of 25.1%, and Dual-Force® and Other Sales amounted to $4.8 million, growing by 10.9%.

#### Operational Insights

ImmuCell Corporation’s growth in the second quarter was significant despite a challenging comparison with the second quarter of 2025, which included substantial sales from distributors replenishing inventory after an extended period of backorders. Commercial efforts during the quarter focused on year-round dairy customers, a more price-sensitive segment, which contributed to the growth of Dual-Force® and Tri-Shield®. The expansion of the commercial team is also contributing to increased customer acquisitions in this segment.

#### Outlook

Management anticipates discussing revenue drivers and complete financial results during a conference call scheduled for Friday, August 14, 2026. ImmuCell Corporation believes that end-customer demand for its products remains strong, particularly in Canada, despite recent international sales declines.

### Related Stocks

- [ICCC.US](https://longbridge.com/en/quote/ICCC.US.md)

## Related News & Research

- [ImmuCell (NASDAQ:ICCC) Announces Earnings Results, Beats Estimates By $0.15 EPS](https://longbridge.com/en/news/295859924.md)
- [ImmuCell Q2 revenue rises on higher distributor volume, price realization](https://longbridge.com/en/news/295840008.md)
- [ICCC: Q2 2026 net income rose to $1.8M on 11.5% revenue growth and a $2M legal settlement](https://longbridge.com/en/news/295842805.md)
- [Skye Bio amends 8-K to set Aug. 24 effective date for reverse stock split](https://longbridge.com/en/news/296471274.md)
- [Valion Bio amends 8-K to report final vote tally on reverse stock split approval](https://longbridge.com/en/news/296531983.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**